Subtype
Lung Neuroendocrine Carcinoma
CI-CAN-00003107Explore in graph →
389 active trials6 approved drugs6 evidence items
- NCIt
- C45569
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003107Explore in graph →
Clinical trials
1,113 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (159)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04675697 | Anlotinib Plus Platinum-etoposide in First-line of Extensive-stage Small-cell Lung Cancer | unknown | Phase 2 | 36 | Xiangya Hospital of Central South UniversityOTHER | 1 | Dec 19, 2020 | clinicaltrials |
| NCT03098030 | Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer | completed | Phase 2 / Phase 3 | 483 | United TherapeuticsINDUSTRY | 23 | Dec 9, 2020 | clinicaltrials |
| NCT04659785 | A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer（FA-ES-SCLC） | unknown | Phase 1 / Phase 2 | 53 | Tianjin Medical University Second HospitalOTHER | 1 | Dec 9, 2020 | clinicaltrials |
| NCT03547804 | A Prospective, Single-center, One-arm Clinical Study of Apatinib Combined With Chemotherapy for Pretreated Patients With Advanced Small Cell Lung Cancer(MK 01) | completed | Phase 2 | 31 | The First Hospital of Jilin UniversityOTHER | 1 | Dec 1, 2020 | clinicaltrials |
| NCT04647357 | A Trial of SHR-1316 Maintenance Therapy for Limited Stage Small Cell Lung Cancer | unknown | Phase 2 | 60 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Nov 30, 2020 | clinicaltrials |
| NCT04620837 | Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy | unknown | Phase 2 | 25 | Chinese Academy of Medical SciencesOTHER | 1 | Nov 9, 2020 | clinicaltrials |
| NCT00415363 | Study of Enzastaurin Versus Placebo in the Treatment of Patients With Brain Metastases of Lung Cancer, After Whole Brain Radiation Therapy | completed | Phase 2 | 109 | Eli Lilly and CompanyINDUSTRY | 5 | Nov 5, 2020 | clinicaltrials |
| NCT03724253 | [68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR)(NeoFIND) | terminated | Phase 2 | 19 | Advanced Accelerator ApplicationsINDUSTRY | 2 | Oct 23, 2020 | clinicaltrials |
| NCT01859741 | A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy(PINNACLE) | terminated | Phase 1 / Phase 2 | 172 | OncoMed Pharmaceuticals, Inc.INDUSTRY | 1 | Sep 9, 2020 | clinicaltrials |
| NCT02499770 | Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC) | completed | Phase 1 / Phase 2 | 122 | G1 Therapeutics, Inc.INDUSTRY | 7 | Aug 21, 2020 | clinicaltrials |
| NCT04501029 | A Study of Gimatecan (ST1481) in Small Cell Lung Cancer | unknown | Phase 2 | 70 | Lee's Pharmaceutical LimitedINDUSTRY | 1 | Aug 6, 2020 | clinicaltrials |
| NCT03026166 | A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 42 | AbbVieINDUSTRY | 5 | Jul 17, 2020 | clinicaltrials |
| NCT03389087 | Study of Apatinib Plus Etoposide Capsule as the Therapy of Advanced Small Cell Lung Cancer | unknown | Phase 2 | 60 | Henan Cancer HospitalOTHER_GOV | 1 | Jul 10, 2020 | clinicaltrials |
| NCT03904719 | CM082 and JS001 in Patients With Advanced Small-cell Lung Cancer (SCLC) | unknown | Phase 2 | 30 | AnewPharmaINDUSTRY | 1 | Jul 9, 2020 | clinicaltrials |
| NCT04453930 | A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy（Irinotecan Plus Platinum）and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer（SCLC） | unknown | Phase 2 | 60 | Peking Union Medical College HospitalOTHER | 1 | Jul 1, 2020 | clinicaltrials |
| NCT01803269 | Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer | terminated | Phase 2 | 29 | University of ChicagoOTHER | 1 | Jun 26, 2020 | clinicaltrials |
| NCT03983759 | Study of Sintlimab Maintenance Therapy in Patients With Extensive Small Cell Lung Cancer | unknown | Phase 2 | 40 | Henan Cancer HospitalOTHER_GOV | 1 | Jun 11, 2020 | clinicaltrials |
| NCT02289690 | Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 221 | AbbVieINDUSTRY | 12 | May 14, 2020 | clinicaltrials |
| NCT00080015 | Diflomotecan (BN80915) Administered Once Every 3 Weeks in Treating Patients With Sensitive Small Cell Lung Cancer (SCLC) | completed | Phase 2 | 9 | IpsenINDUSTRY | 0 | Apr 29, 2020 | clinicaltrials |
| NCT04363255 | First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLC | unknown | Phase 2 | 20 | Taizhou HospitalOTHER | 1 | Apr 28, 2020 | clinicaltrials |
| NCT04314297 | Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study | unknown | Phase 2 | 33 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Mar 19, 2020 | clinicaltrials |
| NCT01876446 | Pegylated Irinotecan NKTR 102 in Treating Patients With Relapsed Small Cell Lung Cancer | completed | Phase 2 | 38 | Roswell Park Cancer InstituteOTHER | 1 | Mar 17, 2020 | clinicaltrials |
| NCT02735980 | A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer | completed | Phase 2 | 133 | Eli Lilly and CompanyINDUSTRY | 10 | Mar 17, 2020 | clinicaltrials |
| NCT03585998 | Chemoradiation With Durvalumab Followed by Durvalumab Maintenance for Limited Disease Small Cell Lung Cancer | unknown | Phase 2 | 51 | Samsung Medical CenterOTHER | 1 | Mar 2, 2020 | clinicaltrials |
| NCT01392352 | HYPAZ: Hypertension Induced by Pazopanib(HYPAZ) | terminated | Phase 2 | 31 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Feb 13, 2020 | clinicaltrials |
| NCT00613626 | Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer | completed | Phase 2 | 74 | Hoosier Cancer Research NetworkOTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT02551432 | Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer(MISP-MK3475) | completed | Phase 2 | 26 | Seoul National University HospitalOTHER | 1 | Feb 10, 2020 | clinicaltrials |
| NCT03613597 | Etoposide Plus Lobaplatin Versus Etoposide Plus Cisplatin for Patients With Limited Small-cell Lung Cancer | unknown | Phase 2 | 118 | Guizhou Medical UniversityOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT03613753 | Irinotecan Plus Lobaplatin Versus Irinotecan in the Second-line Treatment of Small Cell Lung Cancer | unknown | Phase 2 | 72 | ShengFa SuOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT04254471 | This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients | unknown | Phase 2 / Phase 3 | 313 | Haihe Biopharma Co., Ltd.INDUSTRY | 1 | Feb 5, 2020 | clinicaltrials |
| NCT04192682 | Anlotinib Combined With Sintilimab as Second-line Treatment or Beyond in Patients With Small Cell Lung Cancer | unknown | Phase 2 / Phase 3 | 40 | Changzhou Cancer Hospital of Soochow UniversityOTHER | 1 | Jan 6, 2020 | clinicaltrials |
| NCT01880528 | Lisinopril in Reducing Shortness of Breath Caused by Radiation Therapy in Patients With Lung Cancer | completed | Phase 2 | 23 | Mayo ClinicOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT04213937 | Nab-paclitaxel Versus Topotecan As Second-Line Treatment for Patients With Extensive Stage Small Cell Lung Cancer | unknown | Phase 2 | 386 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Dec 30, 2019 | clinicaltrials |
| NCT03700359 | A Study of Lobaplatin/Etoposide With or Without Anlotinib Maintenance Therapy in Patients With ES-SCLC | unknown | Phase 2 | 60 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Nov 29, 2019 | clinicaltrials |
| NCT00388960 | Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung Cancer | completed | Phase 2 | 99 | CelgeneINDUSTRY | 5 | Nov 19, 2019 | clinicaltrials |
| NCT00617409 | To Immunize Patients With Extensive Stage SCLC Combined With Chemo With or Without All Trans Retinoic Acid | completed | Phase 2 | 69 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 8, 2019 | clinicaltrials |
| NCT00375193 | Study of Amrubicin in Patients With Small Cell Lung Cancer Refractory or Progressive to Prior Therapy | completed | Phase 2 | 75 | CelgeneINDUSTRY | 3 | Oct 24, 2019 | clinicaltrials |
| NCT02030184 | Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas | withdrawn | Phase 1 / Phase 2 | 0 | University of Maryland, BaltimoreOTHER | 1 | Oct 17, 2019 | clinicaltrials |
| NCT04128800 | Appatinib Combined With S-1 in the Treatment of Small Cell Lung Cancer | unknown | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Oct 16, 2019 | clinicaltrials |
| NCT00483509 | Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung Carcinoma(NGR007) | completed | Phase 2 | 28 | AGC Biologics S.p.A.INDUSTRY | 1 | Oct 4, 2019 | clinicaltrials |
| NCT02062632 | Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy | terminated | Phase 2 | 5 | Mayo ClinicOTHER | 1 | Oct 1, 2019 | clinicaltrials |
| NCT01025284 | A Study for Participants With Small-Cell Lung Cancer | completed | Phase 2 | 64 | Eli Lilly and CompanyINDUSTRY | 3 | Sep 17, 2019 | clinicaltrials |
| NCT03994744 | Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC | unknown | Phase 2 | 68 | Hunan Cancer HospitalOTHER | 1 | Aug 28, 2019 | clinicaltrials |
| NCT04056949 | Efficacy and Safety of IBI308 and Paclitaxel/Albumin Paclitaxel for SCLC Patients Who Failed Etoposide Chemotherapy | unknown | Phase 2 | 30 | Junling LiOTHER | 1 | Aug 14, 2019 | clinicaltrials |
| NCT02109016 | A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations | terminated | Phase 2 | 18 | Clovis Oncology, Inc.INDUSTRY | 5 | Jul 29, 2019 | clinicaltrials |
| NCT01439568 | A Study of LY2510924 in Participants With Extensive-Stage Small Cell Lung Carcinoma | completed | Phase 2 | 90 | Eli Lilly and CompanyINDUSTRY | 1 | Jul 23, 2019 | clinicaltrials |
| NCT03059797 | Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202) | completed | Phase 2 | 120 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 16, 2019 | clinicaltrials |
| NCT01253369 | Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer | completed | Phase 2 | 33 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 23, 2019 | clinicaltrials |
| NCT01173523 | Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer | completed | Phase 2 | 25 | David M. Jackman, MDOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT02605811 | Temozolomide in Preventing Brain Metastases in Small Cell Lung Cancer | unknown | Phase 2 | 426 | Guangzhou Medical UniversityOTHER | 1 | Mar 28, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Dec 19, 2020source: clinicaltrials